A framework for organizing and selecting quantitative approaches for benefit-harm assessment.
about
Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014Integration of PKPD relationships into benefit-risk analysisQuantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPDBenefits and harms of roflumilast in moderate to severe COPDAspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancerOutcome Preferences in Patients With Noninfectious Uveitis: Results of a Best-Worst Scaling Study.Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis.Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts.
P2860
Q27027259-48C1C148-B167-43A3-B315-F7015581B3FCQ30671571-37AA8AAE-E3A2-45C7-A0D2-54BC92E991E5Q35681671-9C3DC0AF-AC49-4891-849A-8C79BC5DEFECQ35683942-B7A15DA6-60C8-4219-8761-2E487BDE6C42Q35685250-7C5E4C50-5855-4125-996E-030554281FD2Q35794066-80E2E48D-FEBB-48E5-BC84-F5099513B00EQ36228580-D19380D5-B785-422F-87D6-2A55B73EC820Q38211405-9592369A-38DC-423E-ADD9-7643B4C58C46Q38485343-2712581B-94C0-44C9-99B4-551251C13A3DQ38917477-CC6C7989-8996-4627-AC42-0614C5131685Q39134309-EBCA60CF-EC6E-4EBF-AC90-5A10662E7BFBQ55048853-149A9EB8-E6D6-4828-B88E-FB6C22B06E1DQ55278677-D3B6AABD-313A-4AC9-B6E8-75553C5C0159
P2860
A framework for organizing and selecting quantitative approaches for benefit-harm assessment.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A framework for organizing and ...... s for benefit-harm assessment.
@ast
A framework for organizing and ...... s for benefit-harm assessment.
@en
A framework for organizing and ...... s for benefit-harm assessment.
@nl
type
label
A framework for organizing and ...... s for benefit-harm assessment.
@ast
A framework for organizing and ...... s for benefit-harm assessment.
@en
A framework for organizing and ...... s for benefit-harm assessment.
@nl
prefLabel
A framework for organizing and ...... s for benefit-harm assessment.
@ast
A framework for organizing and ...... s for benefit-harm assessment.
@en
A framework for organizing and ...... s for benefit-harm assessment.
@nl
P2093
P2860
P356
P1476
A framework for organizing and ...... s for benefit-harm assessment.
@en
P2093
Carlos O Weiss
Cynthia M Boyd
Milo A Puhan
Ravi Varadhan
P2860
P2888
P356
10.1186/1471-2288-12-173
P50
P577
2012-11-19T00:00:00Z
P5875
P6179
1015579911